Ginkgo Bioworks Holdings, Inc.'s (NYSE:DNA) Shares Climb 45% But Its Business Is Yet to Catch Up

Simply Wall St.

Oct 03

Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) shares have had a really impressive month, gaining 45% after a shaky period beforehand. The last 30 days bring the annual gain to a very sharp 97%. Even...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2572076095"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2572076095\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2572076095?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2025-10-03 18:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2572076095","market":"sg","top_or_hot":-1,"title":"Ginkgo Bioworks Holdings, Inc.'s (NYSE:DNA) Shares Climb 45% But Its Business Is Yet to Catch Up","media":"Simply Wall St.","content":"<div>\n<p>Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) shares have had a really impressive month, gaining 45% after a shaky period beforehand.    The last 30 days bring the annual gain to a very sharp 97%.    Even...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-dna/ginkgo-bioworks-holdings/news/ginkgo-bioworks-holdings-incs-nysedna-shares-climb-45-but-it\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ginkgo Bioworks Holdings, Inc.'s (NYSE:DNA) Shares Climb 45% But Its Business Is Yet to Catch Up</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGinkgo Bioworks Holdings, Inc.'s (NYSE:DNA) Shares Climb 45% But Its Business Is Yet to Catch Up\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-10-03 18:16 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-dna/ginkgo-bioworks-holdings/news/ginkgo-bioworks-holdings-incs-nysedna-shares-climb-45-but-it><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) shares have had a really impressive month, gaining 45% after a shaky period beforehand.    The last 30 days bring the annual gain to a very sharp 97%.    Even...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-dna/ginkgo-bioworks-holdings/news/ginkgo-bioworks-holdings-incs-nysedna-shares-climb-45-but-it\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-dna/ginkgo-bioworks-holdings/news/ginkgo-bioworks-holdings-incs-nysedna-shares-climb-45-but-it","article_id":"2572076095","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-dna/ginkgo-bioworks-holdings/news/ginkgo-bioworks-holdings-incs-nysedna-shares-climb-45-but-it","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2572076095","pubTimestamp":1759486587,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Ginkgo Bioworks Holdings, Inc. ( NYSE:DNA ) shares have had a really impressive month, gaining 45% after a shaky period...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","BK4121":"生命科学工具和服务","DNA":"Ginkgo Bioworks Holdings Inc.","BK4109":"特种化学制品","NYSE":"纽交所"},"translate_title":"Ginkgo Bioworks Holdings,Inc.(NYSE：DNA)股价上涨45%，但其业务尚未迎头赶上","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DNA":1.5,"NYSE":1.5},"content_text":"Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) shares have had a really impressive month, gaining 45% after a shaky period beforehand.    The last 30 days bring the annual gain to a very sharp 97%.    Even after such a large jump in price, there still wouldn't be many who think Ginkgo Bioworks Holdings' price-to-sales (or \"P/S\") ratio of 3.8x is worth a mention when the median P/S in the United States' Life Sciences industry is similar at about 3.7x.  However, investors might be overlooking a clear opportunity or potential setback if there is no rational basis for the P/S.     Trump has pledged to \"unleash\" American oil and gas and these 15 US stocks have developments that are poised to benefit.  View our latest analysis for Ginkgo Bioworks Holdings NYSE:DNA Price to Sales Ratio vs Industry October 3rd 2025Advertisement How Has Ginkgo Bioworks Holdings Performed Recently?  Recent times have been advantageous for Ginkgo Bioworks Holdings as its revenues have been rising faster than most other companies.   One possibility is that the P/S ratio is moderate because investors think this strong revenue performance might be about to tail off.  If you like the company, you'd be hoping this isn't the case so that you could potentially pick up some stock while it's not quite in favour.      If you'd like to see what analysts are forecasting going forward, you should check out our free report on Ginkgo Bioworks Holdings.  Is There Some Revenue Growth Forecasted For Ginkgo Bioworks Holdings?   Ginkgo Bioworks Holdings' P/S ratio would be typical for a company that's only expected to deliver moderate growth, and importantly, perform in line with the industry.   Taking a look back first, we see that the company grew revenue by an impressive 25% last year.    Still, revenue has fallen 57% in total from three years ago, which is quite disappointing.  So unfortunately, we have to acknowledge that the company has not done a great job of growing revenues over that time.     Turning to the outlook, the next year should bring diminished returns, with revenue decreasing 18%  as estimated by the four analysts watching the company.  With the industry predicted to deliver 6.2% growth, that's a disappointing outcome.  With this in consideration, we think it doesn't make sense that Ginkgo Bioworks Holdings' P/S is closely matching its industry peers.  Apparently many investors in the company reject the analyst cohort's pessimism and aren't willing to let go of their stock right now.  Only the boldest would assume these prices are sustainable as these declining revenues are likely to weigh on the share price eventually.    The Bottom Line On Ginkgo Bioworks Holdings' P/S  Ginkgo Bioworks Holdings' stock has a lot of momentum behind it lately, which has brought its P/S level with the rest of the industry.      Generally, our preference is to limit the use of the price-to-sales ratio to establishing what the market thinks about the overall health of a company.  It appears that Ginkgo Bioworks Holdings currently trades on a higher than expected P/S for a company whose revenues are forecast to decline.  When we see a gloomy outlook like this, our immediate thoughts are that the share price is at risk of declining, negatively impacting P/S.  If we consider the revenue outlook, the P/S seems to indicate that potential investors may be paying a premium for the stock.     Plus, you should also learn about these   3 warning signs we've spotted with Ginkgo Bioworks Holdings.  If companies with solid past earnings growth is up your alley, you may wish to see this free collection of other companies with strong earnings growth and low P/E ratios. New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}